Coeptis Therapeutics (NASDAQ:ZSQR) and 8X8 (NASDAQ:EGHT) Head-To-Head Review

8X8 (NASDAQ:EGHT) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

94.0% of 8X8 shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 2.1% of 8X8 shares are owned by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares 8X8 and Coeptis Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
8X8	$735.75 million	0.42	$1.65 million	$0.04	53.00
Coeptis Therapeutics	$1.36 million	143.80	-$11.92 million	($1.63)	-2.26

8X8 has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than 8X8, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

8X8 has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500.

Profitability

This table compares 8X8 and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
8X8	0.64%	28.72%	6.14%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Analyst Ratings

This is a summary of recent ratings and recommmendations for 8X8 and Coeptis Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
8X8	1	1	2	0	2.25
Coeptis Therapeutics	1	0	0	0	1.00

8X8 currently has a consensus target price of $3.12, suggesting a potential upside of 47.41%. Given 8X8’s stronger consensus rating and higher probable upside, equities research analysts clearly believe 8X8 is more favorable than Coeptis Therapeutics.

Summary

8X8 beats Coeptis Therapeutics on 12 of the 14 factors compared between the two stocks.

About 8X8

8×8, Inc. engages in the provision of enterprise communication solutions. It offers solutions to the business services, education, financial services, government, healthcare, and manufacturing industries. The company was founded in February 1987 and is headquartered in Campbell, CA.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.